系统药理学探索人参对抗心力衰竭的潜在机制
1Department of Pharmacy, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Rejuvenation research
|November 6, 2024
概括
人参通过调节PI3K-Akt和AMPK通路来改善心力衰竭 (HF). 关键化合物如金氏化物Rg1和Rb3显示治疗潜力,在老鼠模型中得到验证.
科学领域:
- 药理学 药理学是指药理学的学科.
- 系统生物学 系统生物学
- 心血管研究研究心血管研究
背景情况:
- 心力衰竭 (HF) 仍然是全球疾病和死亡的主要原因.
- 人参 Radix et Rhizoma (人参) 在传统上用于治疗各种疾病,包括心血管疾病的历史悠久.
- 人参在HF中的精确药理机制尚未完全阐明.
研究的目的:
- 阐明人参在心力衰竭 (HF) 中的药理机制.
- 为人参在高血压中临床应用提供理论基础.
- 确定涉及HF治疗的关键人参化合物和分子标.
主要方法:
- 系统药理学方法整合了网络药理学,基因表达综合 (GEO) 分析和分子对接.
- 使用异二醇 (ISO) 诱导的HF大鼠模型进行实验验验证.
- 西部斑点分析以确认信号通路调制.
主要成果:
- 确定了154个潜在的中国人参标对HF;PI3K-Akt,AMPK,MAPK和Ras信号通路至关重要.
- 鉴定出人参化物Rg1和Rb3是针对FN1和PRKAA2.2的关键活性化合物.
- 人参提取物 (EPG) 改善了心脏功能,减少了氧化应激和炎症,并在体内调节了关键蛋白质表达.
结论:
- 人参对HF主要通过PI3K-Akt和AMPK信号通路产生治疗作用.
- 银化物Rg1和银化物Rb3是治疗高血压的潜在治疗剂.
- 这项研究为人参在高温管理中的使用提供了科学依据.
更多相关视频
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.2K
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
503
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:26Heart Failure Drugs: Inotropic Agents
525
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
525
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
01:29Pathophysiology of Cardiac Performance
576
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
576
01:22Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319